MEK Inhibitor Market, By Type (MEKINIST, COTELLIC and MEKTOVI), By Application (Non-Small Cell Lung Cancer and Cancer), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

MEK inhibitor inhibits mitogen-activated protein kinase enzyme MEK1 and MEK2 which affect the MAPK/ERK pathway.  Trametinib is a cancer drug which treats metastatic melanoma carrying BRAF V600E mutation. In this mutation, amino acid valine (V) at position 600 within BRAF is replaced by glutamic acid (E) making the mutant BRAF protein constitutively active. Another drug is also MEK inhibitor used in combination with Vemurafenib. In Nov 2015, U.S. Food and Drug Administration approved COTELLIC for unresectable or metastatic melanoma with BRAF V600E or V600K mutation. This drug is not indicated for treatment of pateints with wild-type BRAF melanoma. Side effects observed co-treated with this drugs include diarrhea, nausea, vomiting, rash, photosensitivity and pyrexia.MEK Inhibitor Market is anticipated to register a CAGR of 8.1%

Impact of Covid-19 pandemic on market

As Covid-19 spread globally, it created disruption across communities, hospital and other healthcare department. Product development got disrupted as research have to adjust to remote work environments and the lab facility was also reduced. Clinical trials were also affected which hampers the MEK inhibitor market

Prevalence of cancer patients

The increase in mortality and morbidity rates among patients is one of the driver of this market. For instance, according to WHO, there are approximately 14 million cancer incidence every year and the rates are constantly increasing. Almost 1.9 million new cancer cases are expected to be diagnosed in 2021.

For diagnosis of Non-small cell lung cancer use of protein biomarker

Protein biomarkers are used for detecting tumors due to their capability of differentiate between morphological as well as chemical features of protein in normal and abnormal cells. Detection of NSCLC through these protein biomarkers which drives the market of MEK inhibitor.

However, side effects of MEK inhibitor, uncertainties in abundance of substitutes and strict regulations from government might hamper growth of the global market to a certain extent.

Source: Prophecy Market Insights

 The Global MEK inhibitor Market is segmented based on the type, application, distribution channel and region. By Type, the Global MEK inhibitor Market is segmented into MEKINIST, COTELLIC and MEKTOVI. By Application, the market is segmented in Non-Small Cell Lung Cancer and Cancer. By Distribution Channel, the Global MEK inhibitor Market is segmented into Hospital pharmacies, Online pharmacies and Others. By region, the Global MEK inhibitor Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

Regional Insights:

On region the Global MEK Inhibitor Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is leading the MEK inhibitor market due to increase in prevalence of Non-small cell lung cancer and increasing sales approvals for drugs boost the market. Europe is second leading region after North America to lead over forecast period due to rising population and developing new technologies.

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the Global MEK Inhibitor Market report based on type, application, distribution channel and region.

Global MEK Inhibitor Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the Global MEK inhibitor Market include AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Novartis AG, Ono Pharmaceutical Co. Ltd., and Pfizer Inc. Companies are continuously rising the production and supply of product to grow this market.

• Thermo Fisher Scientific, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Novartis AG

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies

• Pfizer Inc.
• AstraZeneca Plc
•  F. Hoffmann-La Roche Ltd.
• Ono Pharmaceutical Co. Ltd.

 “*” marked represents similar segmentation in other categories in the respective section